Filing Flows › Comparisons › MCRB vs MIST
Seres Therapeutics vs Milestone Pharmaceuticals: MCRB and MIST compared
Seres Therapeutics is the larger company: $593K of revenue in its latest quarter (Q3 2026) against $559K for Milestone Pharmaceuticals (Q2 2026).
Where the money goes: MCRB and MIST
Seres Therapeutics (MCRB) · Q3 2026
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.
Milestone Pharmaceuticals (MIST) · Q2 2026
Milestone Pharmaceuticals, Q2 2026: revenue $559K, net loss $28.6M, operating cash flow −$22.7M. The chart follows the revenue to costs, profit and cash.
| Seres Therapeutics (MCRB) | Milestone Pharmaceuticals (MIST) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $593K | $559K |
| Revenue growth, Y/Y | +69% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$16.3M | −$28.6M |
| Operating cash flow | −$10.5M | −$22.7M |
Questions
Which is bigger, Seres Therapeutics or Milestone Pharmaceuticals?
Seres Therapeutics is the larger company: $593K of revenue in its latest quarter (Q3 2026) against $559K for Milestone Pharmaceuticals (Q2 2026).
More: Seres Therapeutics earnings · how Seres Therapeutics makes money · Milestone Pharmaceuticals earnings · how Milestone Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.